TWI268777B - Compounds with 5-HT1A activity useful for treating disorders of the outer retina - Google Patents

Compounds with 5-HT1A activity useful for treating disorders of the outer retina Download PDF

Info

Publication number
TWI268777B
TWI268777B TW090106235A TW90106235A TWI268777B TW I268777 B TWI268777 B TW I268777B TW 090106235 A TW090106235 A TW 090106235A TW 90106235 A TW90106235 A TW 90106235A TW I268777 B TWI268777 B TW I268777B
Authority
TW
Taiwan
Prior art keywords
retinal
pharmaceutical composition
rats
retina
org
Prior art date
Application number
TW090106235A
Other languages
English (en)
Chinese (zh)
Inventor
Robert J Collier Jr
Michael A Kapin
Mark R Hellberg
Thomas R Dean
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of TWI268777B publication Critical patent/TWI268777B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
TW090106235A 2000-03-17 2001-03-16 Compounds with 5-HT1A activity useful for treating disorders of the outer retina TWI268777B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19027900P 2000-03-17 2000-03-17

Publications (1)

Publication Number Publication Date
TWI268777B true TWI268777B (en) 2006-12-21

Family

ID=22700682

Family Applications (1)

Application Number Title Priority Date Filing Date
TW090106235A TWI268777B (en) 2000-03-17 2001-03-16 Compounds with 5-HT1A activity useful for treating disorders of the outer retina

Country Status (18)

Country Link
EP (3) EP1263434A1 (enExample)
JP (5) JP2003527423A (enExample)
KR (3) KR20030016239A (enExample)
CN (2) CN1198605C (enExample)
AR (1) AR028258A1 (enExample)
AT (1) ATE247507T1 (enExample)
AU (5) AU2001238552A1 (enExample)
BR (3) BR0109193A (enExample)
CA (3) CA2400637A1 (enExample)
DE (1) DE60100625T2 (enExample)
DK (1) DK1263504T3 (enExample)
ES (1) ES2204848T3 (enExample)
MX (3) MXPA02009071A (enExample)
PL (1) PL203709B1 (enExample)
PT (1) PT1263504E (enExample)
TW (1) TWI268777B (enExample)
WO (3) WO2001070223A1 (enExample)
ZA (1) ZA200206350B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
JP2003527423A (ja) * 2000-03-17 2003-09-16 アルコン、インコーポレイテッド 緑内障処置用の５−ｈｔ２および５−ｈｔ１ａアゴニスト活性を有する化合物
TW593302B (en) * 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
AU2003300915B2 (en) 2002-12-13 2008-08-28 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
JP4808612B2 (ja) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
WO2005058911A2 (en) 2003-12-15 2005-06-30 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8685924B2 (en) 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
WO2008117269A2 (en) 2007-03-28 2008-10-02 Atir Holding S.A. Heterotri cyciii c compounds as serotonergic and/or dopaminergic agents and uses thereof
US8158617B2 (en) 2006-05-16 2012-04-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
HUE040019T2 (hu) 2009-11-09 2019-02-28 Allergan Inc Hajnövekedést stimuláló készítmények és módszerek
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
JP6511401B2 (ja) 2013-02-15 2019-05-15 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 持続型薬物送達インプラント
US12343337B2 (en) 2016-09-29 2025-07-01 The Regents Of The University Of California Compounds for increasing neural plasticity
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
SG11202109111VA (en) 2019-02-27 2021-09-29 Univ California Azepino-indoles and other heterocycles for treating brain disorders
SG11202109020QA (en) 2019-02-27 2021-09-29 Univ California N-substituted indoles and other heterocycles for treating brain disorders
MX2024007221A (es) 2021-12-15 2024-08-27 Delix Therapeutics Inc Psicoplastogenos sustituidos con fenoxi y benciloxi y sus usos.
ES3030316T3 (en) * 2021-12-23 2025-06-27 Cilcare Dev 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02262518A (ja) * 1989-04-03 1990-10-25 Kaken Pharmaceut Co Ltd 眼圧調整剤
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下１▼―ブロッカー点眼剤
TW270114B (enExample) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
JP3958391B2 (ja) * 1995-10-25 2007-08-15 三菱化学株式会社 眼疾患用薬剤
US5998467A (en) * 1995-10-25 1999-12-07 Mitsubishi Chemical Corporation Medicine for oculopathy
WO1998018458A1 (en) * 1996-10-31 1998-05-07 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
JP2003527423A (ja) * 2000-03-17 2003-09-16 アルコン、インコーポレイテッド 緑内障処置用の５−ｈｔ２および５−ｈｔ１ａアゴニスト活性を有する化合物

Also Published As

Publication number Publication date
AU2001239836A1 (en) 2001-10-03
KR20020082885A (ko) 2002-10-31
PL203709B1 (pl) 2009-11-30
WO2001070222A2 (en) 2001-09-27
CN1418100A (zh) 2003-05-14
CN1198605C (zh) 2005-04-27
KR20030016239A (ko) 2003-02-26
DK1263504T3 (da) 2003-12-08
AU2001245310B2 (en) 2005-03-17
AU2005202600A1 (en) 2005-07-07
WO2001070230A3 (en) 2002-04-25
MXPA02009073A (es) 2003-03-12
JP2003527427A (ja) 2003-09-16
PT1263504E (pt) 2003-12-31
KR100749191B1 (ko) 2007-08-13
DE60100625D1 (de) 2003-09-25
JP2011153158A (ja) 2011-08-11
WO2001070223A1 (en) 2001-09-27
MXPA02009071A (es) 2003-05-23
CA2399985A1 (en) 2001-09-27
EP1263504A2 (en) 2002-12-11
PL358306A1 (en) 2004-08-09
JP2011037901A (ja) 2011-02-24
ZA200206350B (en) 2003-08-08
AR028258A1 (es) 2003-04-30
AU2001238552A1 (en) 2001-10-03
BR0109211A (pt) 2003-02-11
JP2003527423A (ja) 2003-09-16
CN1418121A (zh) 2003-05-14
ES2204848T3 (es) 2004-05-01
JP2003527422A (ja) 2003-09-16
BR0109193A (pt) 2003-05-27
WO2001070222A3 (en) 2002-07-25
EP1263434A1 (en) 2002-12-11
AU2005202600B2 (en) 2008-07-31
HK1051504A1 (en) 2003-08-08
EP1267878A2 (en) 2003-01-02
EP1263504B1 (en) 2003-08-20
ATE247507T1 (de) 2003-09-15
DE60100625T2 (de) 2004-02-26
CA2400639C (en) 2011-08-16
MXPA02009072A (es) 2003-03-12
WO2001070230A2 (en) 2001-09-27
AU4531001A (en) 2001-10-03
CA2400637A1 (en) 2001-09-27
KR20030009390A (ko) 2003-01-29
CA2400639A1 (en) 2001-09-27
BR0109230A (pt) 2003-06-03
JP4789231B2 (ja) 2011-10-12

Similar Documents

Publication Publication Date Title
TWI268777B (en) Compounds with 5-HT1A activity useful for treating disorders of the outer retina
AU2001245310A1 (en) Compounds with 5-HT1A activity useful for treating disorders of the outer retina
US20100168121A1 (en) Compounds with 5-ht1a activity useful for treating disorders of the outer retina
DE69423782T2 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
Collier et al. Agonists at the serotonin receptor (5-HT1A) protect the retina from severe photo-oxidative stress
WO2004069181A2 (en) Composition for the treatment of intraocular pressure
KR20020002356A (ko) 외부 망막 손상의 치료
EP4257148A1 (en) Eyedrops for treating scleral thinning and screening method for therapeutic agent of scleral thinning
PL214875B1 (pl) Zastosowanie antagonistów receptorów ß-adrenergicznych do wytwarzania leku do leczenia zaburzen zewnetrznej siatkówki
WO2005079792A1 (ja) 重症糖尿病網膜症の予防又は治療剤
HK1051504B (en) Use of compounds with 5-ht1a activity useful for treating disorders of the outer retina
KR20090034365A (ko) 외부 망막 질환을 치료하는데 유용한 모노아민 산화효소 저해제

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees